LIFITEGRAST - Generic Drug Details

What are the generic sources for lifitegrast and what is the scope of patent protection?

Lifitegrast is the generic ingredient in two branded drugs marketed by Eugia Pharma, Ingenus Pharms Llc, Micro Labs, and Bausch And Lomb Inc, and is included in four NDAs. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lifitegrast has one hundred and fifty-seven patent family members in twenty-five countries.

Three suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for LIFITEGRAST

International Patents:	157
US Patents:	11
Tradenames:	2
Applicants:	4
NDAs:	4
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	69
Clinical Trials:	22
Patent Applications:	2,051
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LIFITEGRAST
What excipients (inactive ingredients) are in LIFITEGRAST?	LIFITEGRAST excipients list
DailyMed Link:	LIFITEGRAST at DailyMed

Recent Clinical Trials for LIFITEGRAST

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bausch & Lomb Incorporated	PHASE3
Bausch & Lomb Incorporated	PHASE2
Lunan Better Pharmaceutical Co., LTD.	PHASE3

See all LIFITEGRAST clinical trials

Generic filers with tentative approvals for LIFITEGRAST

Applicant	Application No.	Strength	Dosage Form
		5%	SOLUTION/DROPS;OPHTHALMIC

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for LIFITEGRAST

Drug Class	Lymphocyte Function-Associated Antigen-1 Antagonist
Mechanism of Action	Lymphocyte Function-Associated Antigen-1 Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for LIFITEGRAST

S01XA	Other ophthalmologicals
S01X	OTHER OPHTHALMOLOGICALS
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for LIFITEGRAST

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XIIDRA	Ophthalmic Solution	lifitegrast	5%	208073	4	2020-07-13

US Patents and Regulatory Information for LIFITEGRAST

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016		RX	Yes	Yes			Y
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016		RX	Yes	Yes			Y	Y
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016		RX	Yes	Yes				Y
Eugia Pharma	LIFITEGRAST	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	215063-001	Nov 7, 2023		DISCN	No	No
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016		RX	Yes	Yes			Y
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016		RX	Yes	Yes			Y	Y

Expired US Patents for LIFITEGRAST

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016

International Patents for LIFITEGRAST

Country	Patent Number	Title	Estimated Expiration
Japan	7008750
Slovenia	1682537
Japan	5840582
World Intellectual Property Organization (WIPO)	2009128934
Canada	2702984	COMPOSITIONS ET PROCEDES POUR LE TRAITEMENT DE LA RETINOPATHIE DIABETIQUE (COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY)
Brazil	112015001608

Supplementary Protection Certificates for LIFITEGRAST

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2444079	C02444079/01	Switzerland		FORMER OWNER: NOVARTIS AG, CH

Market Dynamics and Financial Trajectory for LIFITEGRAST

Last updated: September 9, 2025

Introduction

Lifitegrast, marketed under the brand name Xiidra, is a prescription ophthalmic solution approved by the U.S. Food and Drug Administration (FDA) in 2016 for the treatment of signs and symptoms of dry eye disease (DED). As a novel integrin antagonist, it offers a different mechanism of action compared to traditional artificial tears and anti-inflammatory agents. Understanding the evolving market dynamics and financial trajectory of Lifitegrast is vital for stakeholders including pharmaceutical companies, investors, healthcare providers, and policy makers.

Market Overview

Epidemiology and Market Need

Dry eye disease affects an estimated 16 million Americans, with prevalence rates rising due to aging populations and increased screen time [1]. The condition significantly impacts quality of life and imposes economic burdens, projected to reach $4.3 billion annually in the U.S. alone as of 2020 [2].

Competitive Landscape

Lifitegrast faces competition primarily from Lifitegrast’s main rival, cyclosporine ophthalmic emulsion (Restasis), introduced in 1980s and rebranded as Restasis and subsequently, Cequa (by Sun Pharmaceutical and other players). Recently, emerging drugs like Aximris (various formulations) and novel biologics have entered the space, intensifying competition.

Regulatory and Clinical Positions

The FDA approved Lifitegrast based on clinical trials demonstrating significant improvements in ocular surface disease index (OSDI) scores and other clinical parameters. However, criticisms about its modest efficacy and side effect profile (e.g., dysgeusia, instillation site reactions) have tempered enthusiasm among some prescribers.

Market Dynamics

Drivers

• Increasing Patient Population: Aging demographics and lifestyle factors that aggravate dry eye disease fuel market growth.
• Unmet Clinical Needs: Lack of universally effective treatments for DED sustains demand for innovative therapies such as Lifitegrast.
• Physician Acceptance: As awareness increases, ophthalmologists are increasingly prescribing Lifitegrast, especially in cases unresponsive to artificial tears.
• Insurance Coverage: Payers' coverage policies influence adoption rates; inclusion in formulary and favorable reimbursement can drive sales.

Challenges

• Modest Efficacy: Comparative studies show Lifitegrast provides symptomatic relief comparable but not superior to existing options, limiting growth potential.
• Side Effect Profile: Side effects such as altered taste diminish patient compliance, impacting continuous usage.
• Pricing and Reimbursement: Pricing strategies and reimbursement policies directly impact profit margins and market penetration.
• Market Saturation: With existing competition from cyclosporine and other emerging agents, market penetration faces saturation.

Market Penetration and Adoption Trends

Since launch, Lifitegrast has seen gradual market penetration, with prescribing rates varying geographically. Developed markets like the U.S. record higher adoption, boosted by insurance coverage and physician familiarity. Nevertheless, slow uptake in some regions attributes to clinician inertia and competition.

Strategic Alliances and Intellectual Property

Biotech firms and pharmaceutical companies explore collaborations to expand Lifitegrast indications or develop next-generation integrin antagonists, aiming to extend patent life and market share. Patent protections, expiring by the late 2020s, threaten generics’ entry and impact revenue streams.

Financial Trajectory

Sales and Revenue Growth

Lifitegrast’s commercial success hinges on sales volume and pricing. Initial estimates projected U.S. sales of $220 million in 2022, with expectations to surpass $300 million by 2025, assuming steady market adoption [3]. The growth rate reflects both organic expansion and new patient formulations.

Profitability and Cost Structure

Manufacturing costs are relatively stable, given the established production processes. However, marketing, physician education, and reimbursement negotiations constitute significant expenses. Gross margins likely hover around 50-60%, with net margins influenced by R&D investments, patent protections, and market competition.

Global Market Prospects

European and Asian markets remain largely untapped. Regulatory approval processes are underway in select jurisdictions, with commercialization timelines extending over the next 3-5 years. Expanding globally could significantly influence Lifitegrast’s overall revenue trajectory but entails regulatory and reimbursement challenges.

Pricing Strategies

Premium pricing positions Lifitegrast as a specialty drug, but reimbursement pressures necessitate flexible pricing models. Patient assistance programs and tiered pricing are common approaches to foster access. Price erosion upon patent expiration and biosimilar entry may compress margins, emphasizing the importance of lifecycle management.

Future Outlook and Strategic Considerations

Product Lifecycle Strategies

Steady investment in clinical research to expand indications (e.g., other ocular surface diseases), develop combination therapies, or formulate sustained-release versions could prolong Lifitegrast’s lifecycle. Additionally, addressing safety and efficacy concerns via improved formulations may enhance its market position.

Pipeline and Innovation

Emerging biologics and small molecules targeting inflammatory pathways pertinent to dry eye could challenge Lifitegrast's dominance. Staying ahead through innovation and strategic alliances is crucial.

Regulatory and Market Risks

Potential regulatory delays, revised safety profiles, or unfavorable reimbursement policies could impede growth. Conversely, positive clinical trial results and broadening approvals may accelerate market penetration.

Key Takeaways

• Market demand for dry eye therapies sustains steady expansion, with Lifitegrast positioned as a significant player due to its unique mechanism of action.

• Competition remains intense, especially from cyclosporine-based therapies with proven efficacy, requiring Lifitegraft to differentiate via safety, convenience, or efficacy enhancements.

• Revenue growth is projected to continue modestly, driven by increased prescriptions, geographic expansion, and potential new indications, but faces pricing and patent expiration pressures.

• Innovation and lifecycle management are vital for maintaining market relevance amid evolving competitive and regulatory landscapes.

• Global expansion offers lucrative opportunities, but demands navigating complex regulatory and reimbursement environments.

Conclusion

Lifitegrast’s financial trajectory reflects a cautiously optimistic outlook, underpinned by steady market demand and strategic efforts to expand indications and geographies. Nonetheless, the pharmaceutical landscape for dry eye treatment is characterized by stiff competition, evolving regulatory frameworks, and moderate clinical benefits, necessitating continuous innovation and strategic agility to sustain growth.

---

FAQs

1. How does Lifitegrast compare to cyclosporine (Restasis) in treating dry eye disease?
Lifitegrast offers a different mechanism as an integrin antagonist, with comparable efficacy in symptom relief. However, some studies suggest Lifitegrast may have a faster onset of action and fewer side effects like burning sensation, though both have similar safety profiles. Physician preference varies based on individual patient response and tolerability.

2. What are the primary challenges facing Lifitegrast’s market expansion?
Key challenges include competition from established treatments, modest efficacy, side effects affecting adherence, pricing pressures, and regulatory hurdles in international markets.

3. What is the potential for Lifitegrast to treat other ocular inflammatory conditions?
While primarily approved for dry eye, ongoing research explores its application in conditions like allergic conjunctivitis and ocular surface inflammation, which could diversify revenue streams.

4. How might patent expirations influence Lifitegrast’s revenues?
Patent expirations in the late 2020s could open the market for generics, significantly reducing pricing power and revenues unless lifecycle extension strategies are implemented.

5. What strategic moves could enhance Lifitegrast’s market share?
Investing in new clinical trials, expanding indications, developing sustained-release formulations, forging alliances, and expanding into emerging markets can bolster market share and financial performance.

---

Sources

[1] American Academy of Ophthalmology. "Dry Eye Syndrome." AAO, 2022.
[2] Craig, J.P., & Nelson, J.D. "The Global Burden of Dry Eye Disease." Invest Ophthalmol Vis Sci, 2020.
[3] MarketWatch. "Lifitegrast (Xiidra) Market Size and Forecast." 2022.